Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon alfa-2a in chronic hepatitis D
NCT02731131Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2004
- Primary completion
- May 2009
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegylated interferon alpha in chronic hepatitis D (2 arms), sponsored by Roche. Primary endpoint: Number of Participants With Alanine Aminotransferase (ALT) Normalization Plus Negative Hepatitis D Virus (HDV) Ribonucleic Acid (RNA) at 48 Weeks After End of Treatment. Started Sep 2004; status: completed.
02
Drugs
pegylated interferon alpha
03
Conditions
chronic hepatitis D
Beyond the preview
Go deeper on NCT02731131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02731131.